Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside

Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside 是一种 TRPV1 拮抗剂和 HDAC7 抑制剂,可阻断 TRPV1 介导的钙内流并抑制 p65、IκBα、p38、JNK 和 ERK1/2 的磷酸化,从而抑制 NF-κB 和 MAPK 信号通路,减少促炎细胞因子 IL-1β、IL-6 和 TNF-α 的产生及基因表达,具有强效镇痛活性,可在小鼠模型中提高热痛阈值和机械痛阈值,并可恢复 CD8+ T 细胞向膀胱癌肿瘤的浸润、提升膀胱癌免疫治疗的疗效,因此可用于疼痛和膀胱癌的研究。
产品编号: MS-X57693 纯度: 98.92% CAS No.: 205370-59-8 分子式: C42H32O21 分子量: 872.69
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in Ethanol
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside 是一种 TRPV1 拮抗剂和 HDAC7 抑制剂,可阻断 TRPV1 介导的钙内流并抑制 p65、IκBα、p38、JNK 和 ERK1/2 的磷酸化,从而抑制 NF-κB 和 MAPK 信号通路,减少促炎细胞因子 IL-1β、IL-6 和 TNF-α 的产生及基因表达,具有强效镇痛活性,可在小鼠模型中提高热痛阈值和机械痛阈值,并可恢复 CD8+ T 细胞向膀胱癌肿瘤的浸润、提升膀胱癌免疫治疗的疗效,因此可用于疼痛和膀胱癌的研究。

生物实验数据

生物活性 Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside is a TRPV1 antagonist and HDAC7 inhibitor that blocks TRPV1-mediated calcium influx and inhibits the phosphorylation of p65, IκBα, p38, JNK, and ERK1/2, thereby suppressing the NF-κB and MAPK signaling pathways, reducing the production and gene expression of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α, exhibiting potent analgesic activity by elevating thermal and mechanical pain thresholds in mouse models, and restoring CD8+ T cell infiltration into bladder cancer tumors to enhance the efficacy of bladder cancer immunotherapy, and is therefore useful for research on pain and bladder cancer.
IC50 & Target

TRPV1

 

HDAC7

 

ERK1

 

ERK2

 

IL-1β

 

IL-6

 

体外研究
(In Vitro)

Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside (100 ns) 与人类 TRPV1 形成的复合物比 capsazepine 更稳定,结合自由能为 -117.696 kJ/mol。
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside (1-10 μM; 1 h) 可抑制 Capsaicin (MS-R45786) 诱导的表达人 TRPV1 的 HEK293 细胞内钙内流。
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside (6.25-100 μM; 24 h) 在处理 24 h 后,浓度高达 100 μM 时对 RAW264.7 巨噬细胞无毒性。
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside (2.5-10 μM; 1 h) 可抑制 TNF-α 诱导的 RAW264.7 巨噬细胞中炎症基因的表达。
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside (10 μM; 1 h) 在 10 μM 浓度下可抑制 RAW264.7 巨噬细胞中 TNF-α 诱导的 NF-κB 和 MAPK 信号通路激活,该作用会被 Capsaicin 共处理减弱,提示其活性由 TRPV1 介导。
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside (Compound PINO) (3.13 µM-0.38 nM) 可与重组人 HDAC7 蛋白结合,其 Kd 值为 76.7 nM。
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside (10-200 µM; 48 h) 可特异性抑制过表达 HDAC7 的 T24 和 MB49 膀胱癌细胞中的 HDAC 活性,而对其他 HDAC 亚型或其非组蛋白底物无显著影响。
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside (10-200 µM) 可通过提高 SRSF7 的乙酰化水平与表达量、上调 CCL5 的表达,激活 T24 和 UMUC3 膀胱癌细胞中的 SRSF7-CCL5 通路。

Real Time qPCR

Cell Line: TNF-α-stimulated RAW264.7 macrophage cells
Concentration: 2.5 μM; 5 μM; 10 μM
Incubation Time: 1 h (pre-incubated before TNF-α stimulation)
Result: Reduced TNF-α-induced mRNA expression of IL-1β, IL-6, IL-18, COX-2, TGF-β, and TNF-α in RAW264.7 cells.

Western Blot Analysis

Cell Line: TNF-α-stimulated RAW264.7 macrophage cells
Concentration: 10 μM (pre-incubated before TNF-α stimulation); 10 μM (co-incubated with 10 μM Capsaicin)
Incubation Time: 1 h (pre-incubated before TNF-α stimulation); 1 h (co-incubated with 10 μM Capsaicin)
Result: Reduced TNF-α-induced phosphorylation of p65, IκBα, p38, JNK, and ERK1/2 in RAW264.7 cells.
Had its suppression of NF-κB activation and phosphorylation of p38 and ERK1/2 attenuated by co-treatment with 10 μM capsaicin.
Reduced TRPV1 protein levels in RAW264.7 cells.
体内研究
(In Vivo)

Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside (20 mg/kg;腹腔注射;单次给药) 在 Acetic acid (MS-H89626) 诱导的急性炎症疼痛小家鼠 (Mus musculus) 模型中表现出强效镇痛活性。
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside (20 mg/kg;腹腔注射;单次给药) 可提高小鼠的热痛阈值,热水甩尾试验中延长的甩尾潜伏期证明了这一点。
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside (10-20 mg/kg;腹腔注射;单次给药) 在完全弗氏佐剂 (CFA) (MS-E83942) 诱导的慢性炎性疼痛小鼠模型中表现出剂量依赖性镇痛活性,20 mg/kg 剂量可显著提高机械缩足阈值,并发挥抗炎作用,可降低血清中 IL-1β、IL-6 和 TNF-α 的水平。
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside (20 mg/kg;腹腔注射;单次给药) 可有效缓解小鼠的热诱导及机械性骨癌痛,使机械缩足阈值恢复至接近接种前水平。
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside (Compound PINO) (50 µg/g;腹腔注射;每天给药;2 周) 可通过增加 CD8+ T 细胞的肿瘤浸润并抑制肿瘤生长,提高膀胱癌 (BCa) 对抗 PD-1 免疫治疗的敏感性。

Animal Model: C57BL/6J with Acetic acid (MS-H89626)-induced acute inflammatory pain (male)
Dosage: 20 mg/kg
Administration: i.p.; single dose (1 hour prior to Acetic acid challenge)
Result: Reduced the number of acetic acid-induced abdominal stretches more pronouncedly than Capsazepine (MS-O18968) (20 mg/kg).
Animal Model: C57BL/6J with CFA (MS-E83942)-induced chronic inflammatory pain (male)
Dosage: 10 mg/kg; 15 mg/kg; 20 mg/kg
Administration: i.p.; single dose (7 days post-CFA injection; 20 mg/kg also as standalone treatment without CFA)
Result: Increased the mechanical withdrawal threshold significantly compared to the CFA-induced vehicle group at 20 mg/kg.
Did not produce a significant effect at 10 mg/kg or 15 mg/kg.
Did not alter the mechanical withdrawal threshold compared to the non-CFA control group at 20 mg/kg standalone treatment.
Reduced serum levels of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α compared to the CFA-induced vehicle group. Reduced DRG mRNA expression of pro-inflammatory cytokines (IL-1β, IL-6, IL-18, COX-2, IFN-γ, TNF-α) and Ca2+ signaling-related genes (PKA, PKC, P2X3, CAMK2A, CAMK2B) compared to the CFA-induced vehicle group.
Animal Model: C57BL/6 with bladder cancer(5-week-old female)
Dosage: 50 µg/g
Administration: i.p.; daily for 2 weeks
Result: Inhibited bladder cancer proliferation in vivo.
Showed significantly greater therapeutic efficacy when combined with anti-PD1 antibody than anti-PD1 alone, including reduced tumor volume and tumor weight.
Increased CD8 + T cell tumor infiltration to levels significantly higher than in the single-agent anti-PD1 group.
性状 固体
颜色 White to off-white

化学信息

分子量 872.69
分子式 C42H32O21
CAS No. 205370-59-8

储存&溶解度

储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

Ethanol 中的溶解度 : 25 mg/mL (28.65 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
Ethanol1 mM1.1459 mL5.7294 mL11.4588 mL28.6471 mL
5 mM0.2292 mL1.1459 mL2.2918 mL5.7294 mL
10 mM0.1146 mL0.5729 mL1.1459 mL2.8647 mL
15 mM0.0764 mL0.3820 mL0.7639 mL1.9098 mL
20 mM0.0573 mL0.2865 mL0.5729 mL1.4324 mL
25 mM0.0458 mL0.2292 mL0.4584 mL1.1459 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础